Head-To-Head Analysis: DURECT Corporation (DRRX) & The Competition
DURECT Corporation (NASDAQ: DRRX) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare DURECT Corporation to related businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.
Earnings and Valuation
This table compares DURECT Corporation and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|DURECT Corporation||$16.15 million||-$33.04 million||-6.92|
|DURECT Corporation Competitors||$473.30 million||$171.96 million||-6.93|
DURECT Corporation’s rivals have higher revenue and earnings than DURECT Corporation. DURECT Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
DURECT Corporation has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, DURECT Corporation’s rivals have a beta of 6.57, meaning that their average share price is 557% more volatile than the S&P 500.
Insider and Institutional Ownership
45.8% of DURECT Corporation shares are held by institutional investors. Comparatively, 51.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 10.3% of DURECT Corporation shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for DURECT Corporation and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DURECT Corporation Competitors||1389||4503||12346||313||2.62|
DURECT Corporation currently has a consensus price target of $3.17, suggesting a potential upside of 83.04%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.35%. Given DURECT Corporation’s stronger consensus rating and higher possible upside, equities analysts plainly believe DURECT Corporation is more favorable than its rivals.
This table compares DURECT Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DURECT Corporation Competitors||-4,796.34%||-356.26%||-42.95%|
DURECT Corporation rivals beat DURECT Corporation on 8 of the 12 factors compared.
DURECT Corporation Company Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.